You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 138 No. 1, January 1978 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (8)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Ticrynafen

A Novel Uricosuric Antihypertensive Natriuretic Agent

José G. R. de Carvalho, MD; Francis G. Dunn, MB, MRCP; Steven G. Chrysant, MD, PhD; Edward D. Frohlich, MD

Arch Intern Med. 1978;138(1):53-57.


Abstract

Interest in new diuretics with less side effects has led to the synthesis of ticrynafen, an uricosuric diuretic. This agent was compared with hydrochlorothiazide in a crossover design study involving 12 hypertensive men. Both agents significantly decreased mean arterial pressure from 8% to 18% in eight of the 12 patients. In addition to reducing body weight, these diuretics induced reversible changes in BUN and carbon dioxide content (increased) and plasma concentration of potassium and chloride ions (decreased). The most important change in renal function was a 2.5-fold increase in fractional urate clearance by ticrynafen associated with reduction of serum uric acid by 62%. Thus, ticrynafen is a promising therapeutic agent in hypertension, adding a unique uricosuric effect that should improve patient compliance.

(Arch Intern Med 138:53-57, 1978)



Author Affiliations

From the Hypertension Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City; and the Hypertension Research Section of the Alton Ochsner Medical Foundation, New Orleans. Drs Carvalho and Frohlich are now with the Alton Ochsner Medical Foundation, New Orleans; Dr Dunn is with the Royal Infirmary, Glasgow, Scotland; and Dr Chrysant is with the University of Oklahoma Health Sciences Center.


Footnotes

Accepted for publication Jan 27, 1977.

Reprint requests to Alton Ochsner Medical Foundation, 1516 Jefferson Hwy, New Orleans, LA 70121 (Dr Frohlich).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Diuretics on Urate and Calcium Excretion
Yu et al.
Arch Intern Med 1981;141:915-919.
ABSTRACT  

Evaluation of a New Uricosuric Diuretic--Ticrynafen
Kosman
JAMA 1979;242:2876-2878.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1978 American Medical Association. All Rights Reserved.